3 results match your criteria: "Human Biologicals Institute (A Division of Indian Immunologicals Limited)[Affiliation]"
A Phase II/III multicenter randomized single blind non-inferiority immunogenicity and safety study of TeddyVac™ vaccine of Human Biologicals Institute in healthy subjects of 10 years to 60 years of age.
Infect Dis (Lond)
October 2024
Human Biologicals Institute (A Division of Indian Immunologicals Limited), Hyderabad, India.
Article Synopsis
- The study compared the immunogenicity and safety of TeddyVac, a new tetanus-diphtheria vaccine, with an existing brand to address low vaccination coverage and waning immunity.
- Conducted on 444 subjects across India, the trial assessed antibody responses and safety profiles after administering a single dose of either vaccine.
- Results showed that TeddyVac produced similar or better immune responses and had a good safety profile, indicating it is a viable alternative to the comparator vaccine for individuals aged 10 to 60.
Immunogenicity and safety of Havisure vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study.
Vaccine
October 2023
Human Biologicals Institute (A Division of Indian Immunologicals Limited), Hyderabad, India.
Background: Hepatitis A is an inflammation of the liver caused by the hepatitis A virus (HAV). It is transmitted mainly because of poor personal hygiene via the faecal/oral route through ingestion of contaminated food or water or through the direct contact with an infectious person. Though most of the infected individuals recover from the infection, a few may develop fatal fulminant hepatitis.
View Article and Find Full Text PDFBackground: The goal of 'Measles and Rubella Strategic Framework 2021-2030' is to make "A world free from measles and rubella". To be a part of this journey, Human Biologicals Institute has developed Mebella™ vaccine, which is a lyophilized Measles and Rubella (Live) vaccine. A randomized, single blind, comparative, multicenter Phase II/III trial was conducted to compare the immunogenicity and safety of Mebella™ vaccine with MR-VAC® vaccine in healthy subjects.
View Article and Find Full Text PDF